PALO ALTO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its chairman and chief executive officer, Michael M. Wick, M.D., Ph.D., will provide a corporate overview and update at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York City on Tuesday, February 7, 2006 at 11:40 a.m. Eastern time. A webcast of the presentation will be available via the Telik website, www.telik.com.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications,+1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
